RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

July 31, 2021

Study Completion Date

August 31, 2021

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

Rituximab

Infusion of Mabthera/Rituximab every 6 months

DRUG

Dimethyl fumarate

Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.

DRUG

Sodium Chloride solution

Placebo/Sham infusion every 6 months so that the examining physician (blinded) should not know which patient gets Mabthera or Tecfidera

Trial Locations (17)

Unknown

South Älvsborg Hospital, Borås

Falun Hospital, Falun

Gävle Hospital, Gävle

Saghlgrenska Hospital, Gothenburg

Helsingborg Hospital, Helsingborg

Karlstad Hospital, Karlstad

Halland Hospital Kungsbacka, Kungsbacka

Linköping University Hospital, Linköping

Nyköping Hospital, Nyköping

Örebro University Hospital, Örebro

Östersund Hospital, Östersund

Capio StGöran Hospital, Stockholm

Danderyd hospital, Stockholm

Fredrik Piehl, Stockholm

Karolinska Hospital Huddinge, Stockholm

Umeå University, Umeå

Uppsala Academiska Hospital, Uppsala

All Listed Sponsors
lead

Anders Svenningsson

OTHER

NCT02746744 - RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. | Biotech Hunter | Biotech Hunter